Dehydration News and Research

Latest Dehydration News and Research

New data demonstrating the strength of Novartis' hematology portfolio to be presented

Novartis announced today that new data, including a late-breaking presentation on Tasigna® (nilotinib) 200 mg capsules in a form of chronic myeloid leukemia, demonstrate the strength of the company's hematology portfolio in advancing the care of patients.

2 Dec 2009

Study examines racial disparities in hospitalization for white and black adults with preventable conditions

Receiving prompt treatment for common health problems like diabetes, pneumonia and high blood pressure can save patients trips to the hospital and thousands of dollars in medical care costs.

1 Dec 2009

Allos Therapeutics granted U.S. patent for FOLOTYN

Allos Therapeutics, Inc. today announced that the United States Patent and Trademark Office has issued a patent for the use of FOLOTYN™ (pralatrexate injection) for the treatment of T-cell lymphoma. U.S. Patent No. 7,622,470 was issued to Memorial-Sloan Kettering Cancer Center, SRI International and Southern Research Institute, and expires on November 24, 2025.

30 Nov 2009

News outlets examine sanitation in Ethiopia, Liberia

The Daily Monitor examines efforts underway to improve sanitation and promote hygiene in Ethiopia. According to the country's Ministry of Health, "sanitation coverage of Ethiopia has made progressive achievement reaching 54.8% in the current year from 11.5% in 2003," the newspaper reports.

24 Nov 2009

FDA approves sNDA for pediatric autism drug ABILIFY

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ABILIFY® (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients ages 6 to 17 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods.

20 Nov 2009

System to help identify patients at high risk of developing delirium

A specialist in caring for elderly patients, Turner-Hubbard is a geriatric nurse practitioner trained to quickly spot the sudden changes in mental status that signal the onset of the sudden, severe confusion known as delirium. She knows the hospital “triggers” that can bring on fluctuations in behavior: blood loss during surgery, anesthesia, pain medications and anti-anxiety drugs, infections, dehydration, IV lines and catheters, as well as being immobilized for an extended period of time.

19 Nov 2009

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

Millennium: The Takeda Oncology Company today announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company’s second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March.

18 Nov 2009

Genentech submits sBLAs to the FDA for Avastin

Genentech, Inc., a wholly-owned member of the Roche Group, today announced that the company submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer (first-line treatment). One sBLA is based on the Phase III study AVADO that investigated Avastin in combination with docetaxel chemotherapy.

17 Nov 2009

Updated efficacy results from Allos Therapeutics' FOLOTYN study to be presented at the ASH meeting

Allos Therapeutics, Inc. today announced that abstracts from studies of FOLOTYN™ (pralatrexate injection) were accepted for presentation at the 51st Annual Meeting of the American Society of Hematology (ASH) to be held at the Ernest N. Morial Convention Center in New Orleans, La., from December 5-8, 2009.

12 Nov 2009

Physicians and researchers to develop kidney replacement device for children

When children need kidney dialysis because of disease or congenital defects, doctors are forced to adapt adult-size dialysis equipment. No FDA-approved kidney replacement devices exist that are specifically designed for children.

12 Nov 2009

Ocutec receives CE Mark approval for its first PEG hydrogel-based contact lens product

Ocutec Ltd, the medical devices specialist today announced at the American Academy of Optometry Meeting in Orlando CE Mark approval for its first poly(ethylene )glycol (PEG) hydrogel-based contact lens product. In initial patient acceptance trials, this next generation of lenses has demonstrated superior oxygen permeability compared to existing hydrogel based lenses.

11 Nov 2009

SmarterTravel offers tips for staying healthy while traveling

SmarterTravel®, a comprehensive travel advice resource for the budget-conscious consumer, today offered tips for staying healthy while traveling, including some of the dirtiest parts of the plane you should avoid, especially during a highly contagious cold and flu season.

6 Nov 2009

E. coli outbreak highlights the importance of food safety

Two students from Lincoln Middle School in Lincoln, Rhode Island were hospitalized several days after a field trip to Camp Bournedale in Plymouth, Massachusetts earlier this month. Several other students were also sickened.

24 Oct 2009

PendoPharm introduces an all-natural treatment for head lice

PendoPharm, a division of Pharmascience Inc., is pleased to announce the availability in Canada of Zap(R), an all-natural treatment for head lice.

23 Oct 2009

Millennium commences Vc-R-CHOP Phase II trial for diffuse large B-cell lymphoma

Millennium: The Takeda Oncology Company today announced the initiation of a Phase II clinical trial examining rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with or without VELCADE® (bortezomib) for Injection for patients with a common type of lymphoma. The study will examine previously untreated patients with a genomically defined subtype of lymphoma called non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma.

22 Oct 2009

World Medical Association adopts climate change, task shifting resolutions

At its general assembly in New Delhi, India, the World Medical Association (WMA), "a conglomerate of medical associations around the world," approved a plan that aims "to minimise the risk of increased malnutrition deaths, diseases and injuries due to climate change," IANS/Thaindian News reports (10/17).

20 Oct 2009

Migraine can stimulate alcohol-induced headache

Migraine sufferers, beware. You may be more prone to an alcohol-induced headache after a night of drinking, according to researchers from the Jefferson Headache Center.

19 Oct 2009

Meda Pharmaceuticals introduces Onsolis for treating breakthrough cancer pain

Meda Pharmaceuticals Inc. today announced the launch of Onsolis(TM)(fentanyl buccal soluble film) in the U.S. for the management of breakthrough pain (BTP) in patients with cancer, eighteen years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

13 Oct 2009

Collaborative effort to premiere nation’s second Mobile Emergency Room

In partnership with the Emergency Medical Services (EMS) Agency of Los Angeles County, Long Beach Memorial Medical Center and Miller Children’s Hospital will premiere the nation’s second Mobile Emergency Room (ER) unit today at the 25th Anniversary of the Long Beach International City Bank Marathon and Half Marathon.

12 Oct 2009

BioDelivery Sciences' partner Meda to launch ONSOLIS for managing breakthrough pain

BioDelivery Sciences International, Inc. announced that its commercial partner Meda will launch the FDA-approved ONSOLIS (fentanyl buccal soluble film) next week for the management of breakthrough pain (BTP) in patients with cancer, eighteen years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

8 Oct 2009